SNTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Senti Biosciences Inc (SNTI) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising clinical developments and regulatory designations, its financial performance is weak, and technical indicators suggest a bearish trend. The absence of strong trading signals and options data further supports a cautious approach.
The stock is in a bearish trend with MACD below 0 and negatively expanding, RSI in the neutral zone at 25.699, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The pre-market price of $0.829 is close to the key support level of $0.822, indicating limited upside potential in the short term.
Promising Phase 1 clinical trial results for SENTI-202, showing deep, durable remissions and a favorable safety profile.
Regenerative Medicine Advanced Therapy (RMAT) designation, which may expedite FDA approval.
Plans to discuss pivotal registration program with the FDA in 2026.
Weak financial performance with negative net income (-$18.13M) and EPS (-0.
in Q3
Analysts highlight concerns about the company's cash runway, which remains an overhang on the stock.
Bearish technical indicators and a lack of significant trading trends from hedge funds or insiders.
In Q3 2025, the company reported no revenue growth (0% YoY), a significant drop in net income (-37.21% YoY), and a sharp decline in EPS (-89.06% YoY). The gross margin remained at 0%. Overall, the financials indicate poor performance and limited growth.
Analysts are generally positive on SNTI's clinical prospects. Chardan raised its price target to $13 from $12, citing encouraging efficacy and durability signals for SENTI-202. Leerink initiated coverage with an Outperform rating and a $6 price target, highlighting the potential of Senti's LogicGated gene circuit platform. However, concerns about the company's cash runway persist.
